Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017
Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Trial
- Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001.Pediatric blood & cancer · 2025Trial
- Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Longitudinal Trajectories of Neurocognitive Functioning in Childhood Acute Lymphoblastic Leukemia.Journal of pediatric psychology · 2021Trial
- Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Neurocognitive Functioning in Youth with Type 1 Diabetes Mellitus: Contributions of Trauma Exposure and Symptoms.Journal of pediatric neuropsychology · 2026Article
- Impaired neurocognitive functioning 3 months following diagnosis of high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group.Pediatric blood & cancer · 2023Article
- Neurocognitive and emotional factors predict pain-related healthcare utilization in children with sickle cell disease.Pediatric blood & cancer · 2023Article
- Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
- Assessment of cerebral oxygenation response to hemodialysis using near-infrared spectroscopy (NIRS): Challenges and solutions.Journal of innovative optical health sciences · 2021Article
- Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder.Translational psychiatry · 2021Article
- The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia SurvivorsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2019Review
- Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma.Journal of neuro-oncology · 2019Article
- Cognitive Impairment Associated with Cancer: A Brief Review.Innovations in clinical neuroscience · 2018Review
- Differential Role of mGluR5 in Cognitive Processes in Posttraumatic Stress Disorder and Major Depression.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeNeurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions.
methodsThis study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial.
resultsBaseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges.
conclusionsThe first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.